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The apolipoprotein E (APOE) 34 allele is the best
established genetic risk factor for late-onset
Alzheimer’s disease (LOAD). We conducted
genome-wide surveys of 502,627 single-nucle-
otide polymorphisms (SNPs) to characterize
and confirm other LOAD susceptibility genes.
In 34 carriers from neuropathologically verified
discovery, neuropathologically verified replica-
tion, and clinically characterized replication
cohorts of 1411 cases and controls, LOAD
was associated with six SNPs from the GRB-
associated binding protein 2 (GAB2) gene and
a common haplotype encompassing the entire
GAB2 gene. SNP rs2373115 (p = 9 3 1011)
was associated with an odds ratio of 4.06 (con-
fidence interval 2.81–14.69), which interacts
with APOE 34 to further modify risk. GAB2
was overexpressed in pathologically vulnerable
neurons; the Gab2 protein was detected in
neurons, tangle-bearing neurons, and dystro-phic neuritis; and interference with GAB2 gene
expression increased tau phosphorylation. Our
findings suggest that GAB2modifies LOAD risk
in APOE 34 carriers and influences Alzheimer’s
neuropathology.
INTRODUCTION
Alzheimer’s disease (AD) afflicts about 10% of persons
over 65 and almost half of those over 85 (Evans et al.,
1989) and the number of afflicted persons continues to
grow. To date, researchers have firmly established associ-
ations between four genes and AD risk. Whereas more
than 150 mutations of the presenilin 1 (PS1), presenilin 2
(PS2), and amyloid precursor protein (APP) genes account
for many early-onset AD cases with autosomal dominant
inheritance, the apolipoprotein E (APOE) 34 allele ac-
counts for many cases of late-onset AD (LOAD), with
dementia onset after age 60 (Papassotiropoulos et al.,
2006; Corder et al., 1993, 1994; Farrer et al., 1997). The
APOE gene has three common variants, 32, 33, and 34.
The 32 allele is associated with the lowest LOAD risk, while
each copy of the 34 allele in a person’s APOE genotype isNeuron 54, 713–720, June 7, 2007 ª2007 Elsevier Inc. 713
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GAB2 Modifies LOAD Risk in APOE 34 CarriersTable 1. GAB2 SNPs Implicated in the Neuropathological Discovery, Neuropathological Replication, and Clinical
Replication Cohorts
Neuropathology Discovery Cohort
dbsnp RS ID Position Risk Allele
Freq.
Cases
Freq.
Controls p Valuea
OR
(95% CI)
rs901104 77608147 C 0.89 0.72 4.56E-07 3.24 (2.01–5.20)
rs1385600 77613814 T 0.89 0.71 5.02E-07 3.18 (1.99–5.08)
rs1007837 77618724 C 0.89 0.73 4.78E-06 3.18 (1.99–5.08)
rs2510038 77643682 C 0.90 0.74 8.92E-05 2.44 (1.37–4.36)
rs4945261 77667908 G 0.89 0.72 5.66E-07 3.21 (1.99–5.15)
rs7101429 77670615 A 0.89 0.73 4.62E-05 2.13 (1.21–3.75)
rs10793294 77674051 C 0.82 0.66 2.98E-05 2.45 (1.60–3.77)
rs4291702 77678896 C 0.88 0.70 3.73E-06 3.19 (2.00–5.07)
rs7115850 77722719 C 0.86 0.67 1.60E-07 3.21 (2.04–5.05)
rs2373115 77768798 G 0.88 0.70 4.60E-07 3.21 (2.04–5.05)
a p values were computed using c2 tests. For the overall comparison, the Cochran-Mantel-Haenszel c2 test was used. All
p values are uncorrected.associated with a higher LOAD risk and a younger median
age at dementia onset (Corder et al., 1994; Farrer et al.,
1997). Although twin studies suggest that there are several
susceptibility genes which, along with the APOE 34 allele,
contribute to up to 80% of LOAD cases (Gatz et al., 2006),
discovery of other susceptibility genes has been elusive
(Bertram et al., 2007).
To identify susceptibility genes for common and genet-
ically complex disorders like LOAD, it has been proposed
that it would help to conduct genome-wide surveys of at
least 300,000 single-nucleotide polymorphisms (SNPs)
in unrelated cases and controls, compare the most homo-
geneous samples, and consider interactions between
major and minor genes (Papassotiropoulos et al., 2006;
Kruglyak, 1999; Coon et al., 2007). We individually geno-
typed 502,627 SNPs to characterize and confirm LOAD
susceptibility genes in three separate cohorts of LOAD
cases and controls, including a discovery cohort of
clinically and neuropathologically characterized brain do-
nors, a replication cohort of similarly characterized brain
donors, and a replication cohort of clinically characterized
living subjects. The brain donor cohorts were selected to
exclude clinically misdiagnosed cases and cognitively
normal but neuropathologically affected elderly controls;
the clinical cohort was selected to confirm genetic associ-
ations independent of any brain donor selection bias.
Within each cohort, LOAD cases and controls were strat-
ified into subgroups of APOE 34 carriers and noncarriers,
permitting us to investigate genes that modify LOAD risk
in the 34 carriers and genes that might otherwise be
masked by disproportionately large 34 effects.
RESULTS AND DISCUSSION
We recently demonstrated the feasibility of high-density
genome-wide association studies in our neuropathologi-714 Neuron 54, 713–720, June 7, 2007 ª2007 Elsevier Inc.cally characterized cases and controls, providing empiri-
cal support for the suggestion that the APOE locus is un-
paralleled in its contribution to LOAD risk (Coon et al.,
2007). With the exception of an SNP only 14 kb pairs distal
to and in linkage disequilibrium (LD) with the APOE 34
variant on chromosome 19, no other SNP distinguished
LOAD cases from controls after Bonferroni correction for
multiple comparisons (Figure S1A at http://www.tgen.
org/neurogenomics/data). For the previously noted rea-
sons, we divided each cohort into two subgroups: allelic
APOE 34 carriers (Figure S1B) and APOE 34 noncarriers
(Figure S1C). We now report associations between a
common gene and LOAD in APOE 34 carriers in our three
cohorts; we show that the implicated gene is associated
with AD neuropathology in neuronal microarray and immu-
nohistochemical studies; and we consider a possible
mechanism by which GAB2 modifies AD risk in a small-
interfering RNA (siRNA) study. Finally, we deposit all of
the data into the public domain for use by the community
(http://www.tgen.org/neurogenomics/data).
High-Density Genome-Wide Association Studies
Genome-wide genotyping was performed on each indi-
vidual sample from a ‘‘neuropathological discovery co-
hort’’ of 736 brain donors, a ‘‘neuropathological replication
cohort’’ of 311 brain donors, and an additional ‘‘clinical
replication cohort’’ of 364 living subjects who were at least
65 years old at the time of their death or last clinical as-
sessment and who were independently assessed for their
APOE genotype. For the two neuropathological cohorts,
brain tissue for DNA extraction, neuropathological diagno-
ses, and data were supplied by investigators from 20
of the National Institute on Aging (NIA)-sponsored Alz-
heimer’s Disease Centers (ADCs) (in accordance with
agreements with the NIA, the ADCs, and the National Alz-
heimer’s Coordinating Center) and from the Netherlands
Neuron
GAB2 Modifies LOAD Risk in APOE 34 CarriersNeuropathology Replication Cohort Clinical Replication Cohort Overall
Freq.
Cases
Freq.
Controls p Valuea
OR
(95% CI)
Freq.
Cases
Freq.
Controls p Valuea
OR
(95% CI) p Valuea
OR
(95% CI)
0.87 0.73 4.52E-02 2.54 (0.90–7.17) 0.89 0.80 1.47E-01 2.08 (0.76–5.88) 1.99E-06 2.87 (1.84–4.50)
0.88 0.70 1.32E-02 3.00 (1.09–8.24) 0.95 0.78 4.63E-02 5.56 (0.89–33.33) 2.81E-09 3.65 (2.34–5.71)
0.89 0.73 3.20E-02 2.85 (1.00–8.11) 0.88 0.80 2.04E-01 1.89 (0.70–5.00) 3.97E-07 3.01 (1.94–4.68)
0.88 0.75 4.35E-02 2.53 (0.88–7.32) 0.89 0.80 1.47E-01 2.08 (0.76–5.88) 1.19E-05 2.72 (1.72–4.31)
0.88 0.73 4.20E-02 2.54 (0.90–7.17) 0.95 0.78 4.63E-02 5.56 (0.89–33.33) 3.06E-08 3.44 (2.18–5.43)
0.89 0.73 1.87E-02 2.84 (1.00–8.11) 0.88 0.75 4.99E-02 2.50 (0.98–6.25) 1.06E-06 2.96 (1.89–4.63)
0.80 0.59 1.34E-02 2.66 (1.06–6.57) 0.88 0.61 2.17E-02 4.45 (1.18–16.95) 1.59E-07 2.83 (1.90–4.21)
0.87 0.72 2.44E-02 2.70 (0.97–7.52) 0.88 0.80 2.04E-01 1.89 (0.70–5.00) 5.88E-07 2.96 (1.91–4.59)
0.86 0.72 3.91E-02 2.48 (0.90–6.81) 0.98 0.72 3.45E-03 14.93 (1.61–140.85) 2.80E-10 3.92 (2.51–6.11)
0.86 0.72 3.91E-02 2.48 (0.90–6.81) 0.98 0.72 3.45E-03 14.93 (1.61–140.85) 9.66E-11 4.06 (2.81–14.69)Brain Bank. For the hypothesis-testing clinical replication
cohort, DNA extracted from blood, clinical diagnoses, and
data from subjects assessed in Rochester, MN were sup-
plied by investigators from the Mayo Clinic.
The neuropathological discovery cohort included 446
LOAD cases (299 34 carriers and 147 34 noncarriers) and
290 controls (61 34 carriers and 229 34 noncarriers); the
neuropathological replication cohort included 197 LOAD
cases (113 34 carriers and 84 34 noncarriers) and 114 con-
trols (27 34 carriers and 87 34 noncarriers); and the clinical
replication cohort included 218 LOAD cases (115 34
carriers and 103 34 noncarriers) and 146 controls (29 34
carriers and 117 34 noncarriers). Brain donor cases satis-
fied clinical and neuropathological criteria for LOAD, and
were age 73.5 ± 6.2 at death. Brain donor controls did
not have significant cognitive impairment or significant
neuropathological features of AD, and were age 75.8 ±
7.5 at death. Clinical cases satisfied criteria for probable
AD, and were age 78.9 ± 7.8 at last clinical visit. Clinical
controls did not have clinically significant cognitive impair-
ment and were age 81.7 ± 6.6 at last clinical assessment.
We initially surveyed SNPs in the neuropathological
discovery cohort to explore LOAD associations in the 34
carrier and noncarrier subgroups. Within the discovery
subgroup of APOE 34 carriers, 10 of the 25 SNPs with
the most significant LOAD-association significance levels
(contingency test p = 9 3 105 to 1 3 107; uncorrected
for multiple comparisons) were located in the GRB-asso-
ciated binding protein 2 (GAB2) gene on chromosome
11q14.1 (Table 1). LOAD associations in six of these
SNPs were then confirmed in both the neuropathological
replication and clinical replication cohorts (Table 1). These
ten SNPs were not significantly associated with LOAD in
the APOE 34 noncarrier group (contingency test p = 0.08
to 0.97) (Table S1A). Combining data from all 644 APOE
34-carrying cases and controls, we found highly signifi-
cant associations between LOAD and all ten GAB2SNPs (contingency test p = 1.19 3 105 to 9.66 3
1011), with five of the six consistently implicated alleles
surviving the highly conservative Bonferroni correction
for 312,316 independent comparisons (p = 1.55 3 107)
(Table 1). When data from the 34 carriers and noncarriers
were analyzed together, as in our previous report (Coon
et al., 2007), the ten GAB2 SNPs were still associated
with LOAD (contingency test p = 0.013 to 2.7 3 106,
Table S1B), but these associations did not survive Bonfer-
roni correction.
The PLINK analysis toolset (http://pngu.mgh.harvard.
edu/purcell/plink/index.shtml) was used for whole-
genome analysis. Haploview v3.32 was used to determine
the LD structure of the chromosome 11q14.1 region sur-
rounding GAB2 in each of the three APOE 34-stratified
cohorts (Figure 1). Three haplotype blocks are present in
this region: one block upstream of GAB2, roughly corre-
sponding to the ALG8 locus; one 189 kb-pair block
encompassing most of the GAB2 locus; and one down-
stream block corresponding to the NARS2 locus. These
blocks were consistent with the LD structure of the Hap-
Map CEPH populations. The GAB2 gene is completely
encompassed by a single haplotype block extending
from rs901104 to rs2373115 (SNPs 5–22 in Figure 1),
which has three major haplotypes: an extremely common
‘‘GAB2 risk haplotype,’’ a common ‘‘GAB2 protective
haplotype,’’ and a relatively uncommon GAB2 haplotype
unrelated to LOAD risk in APOE 34 carriers (Figure 1). In
all three cohorts, the GAB2 CT-AAG-CAGATCAGACG
haplotype was associated with higher LOAD risk, the
GAB2 TC-GCA-TGAGGTGTCTT haplotype was associ-
ated with a lower LOAD risk, and the CT-AAG-CAGAGCA
GCCG was unrelated to LOAD risk in the APOE 34 carriers
(Figure 1).
Data from the 1411 subjects (including 644 APOE 34
carriers and 767 noncarriers) in all three cohorts were
combined to characterize odds ratios (ORs) and 95%Neuron 54, 713–720, June 7, 2007 ª2007 Elsevier Inc. 715
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GAB2 Modifies LOAD Risk in APOE 34 CarriersFigure 1. Linkage Disequilibrium Struc-
ture and Haplotype Significance Levels
for the Region Encompassing GAB2
Plots follow the Haploview GOLD heatmap
color scheme. SNP numbers correspond to
the following dbSNP ID identification
numbers: 1:rs579711, 2:rs977978,
3:rs637149, 4:rs977977, 5:rs901104,
6:rs1385600, 7:rs11237419, 8:rs1007837,
9:rs2450130, 10:rs2510054, 11:rs11237429,
12:rs2510038, 13:rs2511170, 14:rs4945261,
15:rs7101429, 16:rs10793294, 17:rs4291702,
18:rs11602622, 19:rs10899467, 20:rs2458640,
21:rs10793302, 22:rs2373115, 23:rs12280198,
24:rs12287010, 25:rs17136630, 26:rs4945276,
27:rs1996172, 28:rs7395344, 29:rs11237522,
and 30:rs7950813. In all three cohorts, there
was a GAB2 risk haplotype, a protective haplo-
type, and a haplotype unrelated to LOAD risk in
APOE 34 carriers.confidence intervals (CIs) for rs2373115, the most signifi-
cant SNP in our screen (Table 2). In 34 carriers, LOAD
cases had a risk genotype frequency of 0.88 and controls
had a frequency of 0.71. In comparison with the other 34
carriers, those with rs2373115 genotype GG had a signifi-
cantly higher risk of LOAD (OR 2.36, 95% CI 1.55–3.58)
than those with genotype GT and TT. In contrast, APOE
34 noncarriers with rs2373115 genotype GG did not
have a higher LOAD risk than the other 34 noncarriers
(OR 1.01, 95% CI 0.74–1.38).
Whereas we confirmed a younger age at dementia
onset in the APOE 34 carriers than in noncarriers (age
75.5 ± 7.2 versus 77.8 ± 7.9, p = 2.4 3 104, two-tailed
unpaired t test; unequal variance is statistical test used
for all tests), there was no significant effect of rs2373115
genotype on age at dementia onset in either the 34 carriers
(t test, p = 0.32) or noncarriers (t test, p = 0.84).
Neuronal Microarray Studies
To provide converging evidence that GAB2 is biologically
relevant to AD neuropathology, expression profiling using
the Affymetrix Human Genome U133 Plus 2.0 array was
used to characterize and compare GAB2 expression in716 Neuron 54, 713–720, June 7, 2007 ª2007 Elsevier Inc.laser-capture microdissected non-tangle-bearing neu-
rons of cases and controls in six brain regions differentially
affected by AD. LOAD cases had significantly greater neu-
ronal GAB2 expression in the posterior cingulate cortex
(9 cases, 13 controls, 4.50-fold change, t test, p =
0.00039) and hippocampus (9 cases, 13 controls, 2.94-
fold change, t test, p = 0.00085), and no significant
expression differences in the entorhinal cortex (10 cases,
13 controls, 1.20-fold change, t test, p = 0.46), middle
temporal gyrus (13 cases, 12 controls, 1.44-fold change,
t test, p = 0.14), superior frontal gyrus (22 cases, 11 con-
trols, 1.25-fold change, t test, p = 0.47), or primary visual
cortex (17 cases, 12 controls, 1.53-fold change, t test,
p = 0.14).
The hippocampus is known to be especially vulnerable
to AD-related neurofibrillary tangles (Braak and Braak,
1991), neuronal loss, and brain atrophy (Bobinski et al.,
2000). It is preferentially involved in AD-related memory
impairment (Jack et al., 1999) and is associated with
the highest cerebral Gab2 expression in the rodent brain
(Lein et al., 2007). The posterior cingulate cortex is known
to be preferentially vulnerable to AD-related hypometa-
bolic abnormalities and fibrillar amyloid deposition, and is
Neuron
GAB2 Modifies LOAD Risk in APOE 34 CarriersTable 2. GAB2 LOAD Odds Ratios in APOE 34 Carriers and Noncarriers
APOE 34 group APOE 34 OR (95% CI) rs2373115 genotype Controls (n) Cases (n) % LOAD rs2373115 OR (95% CI)a
APOE 34 GG 314 232 42.4% 1.12 (0.82–1.53)
GT/TT 121 100 45.2%
APOE 34+ GG 63 406 86.6% 2.88 (1.90–4.36)
GT/TT 54 121 69.1%
All samples 6.07 (4.63–7.95) GG 377 638 62.9% 1.34 (1.06–1.70)
GT/TT 175 221 55.8%
a All rs2373115 ORs are calculated using GG versus GT/TT.also involved in AD-related memory impairment (Reiman
et al., 1996, 2005; Johnson et al., 2006; Buckner et al.,
2005; Mintun et al., 2006). While the entorhinal cortex
and temporal and prefrontal regions are also affected by
AD neuropathology, the visual cortex is relatively spared.
Using a repeated measures analysis of variance to ana-
lyze neuronal GAB2 gene expression data from the same
eight LOAD cases and ten controls, there was a signifi-
cant group-by-region interaction (p = 0.011), with LOAD-
related increases in neuronal GAB2 gene expression that
were greater in the posterior cingulate cortex and hippo-
campus than in the visual cortex.
Tau Phosphorylation siRNA Study
In addition to its other properties, GAB2 is the principal
activator of the phosphatidylinositol 3-kinase (PI3K) sig-
naling pathway (Pratt et al., 2001). PI3K activates Akt,
which in turn promotes glycogen synthase kinase-3
(Gsk3) phosphorylation/inactivation. This mechanism
suppresses Gsk3-dependent phosphorylation of tau at
AD-related hyperphorylated tau residues, the principal
component of neurofibrillary tangles, and prevents apo-
ptosis of confluent cells (Baki et al., 2004; Kang et al.,
2005). Based on these findings, we hypothesized that
Gab2 might function to protect cells from neuronal tangle
formation and cell death and that a loss-of-function GAB2
haplotype would diminish such protection. We thus postu-
lated that interference with GAB2 expression using siRNA
treatment would increase tau phosphorylation at the
serine-262 residue known to be hyperphosphorylated in
AD. As shown in Figure 2, GAB2 siRNA treatment was
associated with a 1.70-fold increase in serine-262 phos-
phorylated tau. This increase was not attributable to
a concomitant increase in total tau levels. Additional
siRNA and protein validation studies are now being per-
formed to determine the extent to which GAB2 affects
tau phosphorylation at additional relevant epitopes.
Immunohistochemical Validation
Gab2 immunohistochemistry was assessed in hippocam-
pus and posterior cingulate cortex in LOAD cases. In
hippocampus, Gab2 immunoreactivity was observed in
structures with the morphology of dystrophic neurites or
neuropil threads, neurons, and corpora amylacea. The pu-tative neurons were almost entirely dystrophic in appear-
ance (Figure 3A) or had cytoplasmic inclusions resembling
neurofibrillary tangles (Figure 3B). Dystrophic neurons and
neurites (Figure 3C) and neurofibrillary tangle-bearing
cells (Figure 3D) were also revealed by the Gab2 antibody
in posterior cingulate. Here, however, many relatively nor-
mal neurons were observed as well, with long stretches of
immunoreactive apical dendrites ascending through the
cortical layers (Figures 3C and 3D).
Discussion
In order to characterize and confirm associations between
the GAB2 gene and LOAD risk in APOE 34 carriers, our
studies capitalized on the genome-wide survey of more
than 300,000 SNPs, two clinically characterized and neu-
ropathologically verified cohorts of AD cases and controls,
a third cohort of clinically well characterized subjects, and
stratification of the samples with respect to carriers and
noncarriers of a major LOAD susceptibility gene, APOE.
Six SNPs that are part of a common haplotype block
encompassing the entire GAB2 gene were implicated in
three independent cohorts. Maximal significance of the
Figure 2. siRNA Knockdown of GAB2 Increases Tau Phos-
phorylation
In comparison with vehicle treatment (red, upper left), GAB2 siRNA
treatment resulted in a 1.70-fold increase in tau phosphorylation at
the serene-262 residue (red, lower left), which is phosphorylated in
LOAD neurofibrillary tangle-bearing neurons. This fold-change was
not attributable to an increase in total tau (green, upper and lower right).Neuron 54, 713–720, June 7, 2007 ª2007 Elsevier Inc. 717
Neuron
GAB2 Modifies LOAD Risk in APOE 34 Carriersassociation was at SNP rs2373115 (p = 93 1011) with an
odds ratio of 4.06 (CI 2.81–14.69). An odds ratio of 24.64
(CI 7.44–116.79) for overall genetic risk is achieved when
both 34 and the GAB2 rs2373115 risk alleles are present.
Data from a microarray study of laser-capture microdis-
sected neurons in LOAD cases and controls, immunohis-
tochemistry, and an siRNA study provided converging ev-
idence for the relevance ofGAB2 to the neuropathology of
LOAD, raising testable hypotheses about the mechanisms
by which GAB2 could modify LOAD risk in 34 carriers and
provide targets at which to aim new treatments.
Although only one genotyping platform was used in all
three cohorts, our findings are unlikely to be attributable
to any platform-related bias in genotyping calls because
the observed association was not limited to a single SNP
but was related to a large haplotype block in agreement
with the LD structure of the HapMap CEPH population.
Furthermore, all six of the implicated SNPs had high-
quality SNiPer-HD scores (greater than 0.45), indicating
that the data for each SNP clustered well (see Figure S2
for cluster diagrams).
Figure 3. Gab2 Colocalizes with Dystrophic Neurons in the
AD Brain
(A) LOAD hippocampus (neutral red counterstain) (403 objective). The
arrow indicates a highly dystrophic cell with the size and morphology
of a cortical pyramidal neuron. Arrowheads point to one of many struc-
tures in the sections that resemble dystrophic neurites or neuropil
threads. (B) LOAD hippocampus (neutral red counterstain) (403).
The arrow denotes a putative neurofibrillary tangle-containing neuron.
Arrowheads again indicate a dystrophic neurite. (C) LOAD posterior
cingulate gyrus (403). Filled arrows point to normal-appearing putative
neurons. The open arrow points to a cell with the features of a neurofi-
brillary tangle-bearing neuron. Immunoreactive structures clearly re-
sembling pyramidal cell apical dendrites were also observed ascend-
ing through the cortical layers (arrowheads). (D) LOAD posterior
cingulate cortex (1003 objective). Shown is a Gab2 immunoreactive
cell with the flame-shaped cytoplasmic inclusion typical of the neuro-
fibrillary tangle.718 Neuron 54, 713–720, June 7, 2007 ª2007 Elsevier Inc.Individual genotype data forall samples across >300,000
high-quality SNiPer-HD calls (see Experimental Proce-
dures for QC metrics) is made available to the community
as a .ped file at http://www.tgen.org/neurogenomics/data.
This genome-wide scan data will enable replication of
putative common LOAD risk alleles, and also enable further
discovery of both independent and combinatorial genetic
associations.
The GAB2 haplotype block spans 189 kb and includes
at least 614 known SNPs. Four of the six hundred and
fourteen known SNPs in this locus are nonsynonymous
coding SNPs, which are generally considered to be the
best candidates for functional variation. However, all
four of these SNPs are reported to have minor allele fre-
quencies of 0.0% in the CEPH population (The Interna-
tional HapMap Consortium, 2005), and therefore are not
candidates for the common functional variant on the
GAB2 risk haplotype.
GAB2 is a scaffolding protein involved in multiple signal-
ing pathways, which could affect AD-related tau, amyloid,
metabolic, or other aspects of AD pathology and cell
survival in different ways (Koncz et al., 2002; Gu et al.,
2001; Zompi, Gu and Colucci, 2004), and it has been
found to be coexpressed with other putative AD-related
genes (Li et al., 2004a). Discovery of this LOAD suscepti-
bility gene, if further replicated, provides new opportuni-
ties to investigate LOAD pathogenesis, predisposition,
treatment, and prevention. Genome-wide studies using
even higher density platforms and compound genetic
analyses in sufficiently large samples of well-character-
ized cases and controls promise to play increasingly im-
portant roles in the scientific understanding, evaluation,
treatment, and prevention of AD and other common and
genetically complex disorders. In the interim, public ac-
cess to the raw genotyping data from our series will pro-
vide valuable information to assess the contribution of
other putative risk loci to this devastating disease.
EXPERIMENTAL PROCEDURES
High-Density Genome-Wide Association Study
The 500K GeneChip (Affymetrix, Santa Clara, CA) was used to survey
502,267 SNPs in each subject as recently described (Coon et al.,
2007). Genotypes were extracted using both SNiPer-HD (Hua et al.,
2007) and BRLMM (Affymetrix) software. 312,316 SNPs were analyzed
after excluding those that were monomorphic, did not cluster into three
distinct Gaussian distributions, clustered poorly, had Hardy Weinberg
equilibrium p values less than 0.01, had minor allele frequencies less
than 2%, or exhibited less than 98% concordance between the
SNiPer-HD and BRLMM calls. The software program STRUCTURE
(Pritchard et al., 2000) was employed to test for underlying genetic
stratification using 5000 randomly selected SNPs and including at
least 100 SNPs per chromosome. The initial analysis yielded empirical
evidence of three populations. Since 14 subjects belonged to a popu-
lation far removed from the rest of the study population, they were
eliminated from further analyses. STRUCTURE then was used to dem-
onstrate a comparable admixture of the two populations in the cases
and controls. After stratifying the LOAD cases and controls for pres-
ence or absence of the APOE 34 allele, allelic c2 statistics were com-
puted for each SNP. APOE genotypes were obtained in each subject
Neuron
GAB2 Modifies LOAD Risk in APOE 34 Carriersby either pyrosequencing (Ahmadian et al., 2000) or restriction frag-
ment length polymorphism (RFLP) analysis (Lai et al., 1998).
LD mapping was performed by importing genotypes into the Haplo-
View program v3.32. Pairwise LD values (as measured byD0) reflect the
likelihood that two genetic markers are inherited together.
Neuronal Microarray Studies
Brain samples (mean post-mortem interval of 2.5 hr) from six brain
regions that are either histopathologically or metabolically relevant to
LOAD and aging were collected at the Sun Health Research Institute.
Expression profiling was performed as described previously (Liang
et al., 2007). Direct case-to-control comparisons were performed to
analyze expression differences in each region.
Immunohistochemical Validation
Gab2 immunoreactivity in LOAD hippocampus and posterior cingulate
cortex was examined using an affinity-purified goat polyclonal
antibody directed against a C-terminal epitope of Gab2 (Santa Cruz
Biotechnology, Santa Cruz, CA). Blocks were obtained from rapid
autopsy LOAD cases (<3 hr postmortem) (n = 5). Hippocampus
sections were derived from blocks that were fixed for 24 hr in 4%
paraformaldehyde and sectioned at 40 mm on a freezing microtome.
Posterior cingulate sections were derived from snap-frozen blocks
that were sectioned at 6 mm on a cryostat. Immunohistochemical
protocols were as previously described (Li et al., 2004b). Immunoreac-
tivity was visualized with nickel-intensified diaminobenzidine.
Tau Phosphorylation siRNA Study
Neuroglioma cells overexpressing wild-type tau protein were grown
in 96-well plates and transfected with siRNA directed at GAB2
mRNA. Following 4 days of transfection, cells were fixed, perme-
ablized, and immunostained with antibodies against total tau pro-
tein and tau protein phosphorylated on serine-262. A FITC- and
Cy5-conjugated secondary antibody cocktail was then applied.
After incubation and washing, images were captured and quanti-
tated using the InCell imager 3000 (General Electric). The fold in-
crease in serine-262 phosphorylated tau levels was calculated
against control samples that had been transfected with a scrambled
siRNA sequence.
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